How much does compounded semaglutide cost in 2026?
Expect about $150 to $300 a month for compounded semaglutide in 2026 through a supervised telehealth provider, with intro months often near $150 to $180 and a small membership fee on some plans. A figure worth trusting is one tied to a real prescriber and a named 503A pharmacy behind it, and by that measure FormBlends ranks first.
Price is the question that brings most people here, so I will answer it directly and then complicate it, because a semaglutide number means nothing without knowing who stands behind it. A $99 vial from a site that calls its contents a research chemical is not a bargain version of a $250 prescription. It is a separate product with no clinician, no pharmacy license, and no one answerable if the dose or the molecule is wrong. I sorted the 2026 options by what they charge and by who is accountable, since for a weekly injectable the two travel together.
One legal point belongs up front, because it shapes every price below. Compounded semaglutide is not an FDA-approved product. The agency declared the semaglutide shortage resolved on February 21, 2025, the broad enforcement discretion that let companies mass-market compounded GLP-1 wound down across that year, and in 2026 the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B bulk substances list. A 503A pharmacy can still prepare semaglutide for one patient under a valid prescription where a clinician judges it appropriate, the lane the supervised providers here work inside. The goal is not to hunt the lowest sticker on the internet, but to compare prices that come with a doctor and a real pharmacy.
How I ranked these eight
I scored each option on what a buyer can actually confirm, and for an injected medication I put the prescriber requirement and the pharmacy of record ahead of the headline rate.
- Is a prescriber required first? A licensed clinician has to review you and write the order before semaglutide ships, the line between treatment and a self-directed purchase.
- Is there a real pharmacy behind the price? An FDA-registered 503A pharmacy operating under USP-797 and cGMP, named where possible.
- Is the quote honest and whole? Does the advertised rate include the membership, the dose escalation, and shipping, or does a teaser number hide them.
- Is the source straight about FDA status? Compounded semaglutide is not FDA-approved, and a provider should say so without hedging.
- Does it fit the 2026 framework? Inside supervised compounding, not the research-use-only grey zone now drawing FDA warning letters.
One source below sells semaglutide for research use only, judged on its real attributes. A research-use-only seller is not a fraud by definition, just a different category with no prescriber and no pharmacy, which is why its price cannot be compared like-for-like against a supervised program no matter how low it goes.
The ranking: 8 semaglutide sources in 2026, best to least
1. FormBlends: 9.6/10
FormBlends takes the top spot because the price you pay buys an ongoing clinical relationship rather than a one-off transaction, and that continuity is what a GLP-1 patient actually needs. Semaglutide is a months-long course with a climbing dose, side effects to manage, and refills that have to keep arriving, and FormBlends is built around that arc: one account covers a wide catalog across 47 states, the per-vial cash price is posted before you commit, delivery runs cold-chain at no extra charge, a care team is reachable around the clock, and a free reconstitution calculator helps when you are mixing a vial yourself. Underneath the convenience sits the part that earns the rank: a licensed physician reviews your intake and writes the prescription before any semaglutide leaves the pharmacy, and that pharmacy is an FDA-registered 503A facility working to USP-797 and cGMP, preparing the medication for you by name rather than bottling it as a lab reagent, with HPLC, mass-spec, and endotoxin checks as standard procedure. FormBlends also says plainly that compounded products are not FDA-approved, and it does not market a certification number you can look up, so do not choose it on that basis. It wins on the supervised, prescription-required, 503A model and a price that stays attached to real care. A 2026 editorial on the weight-management medication market, Weight Management Medication: The Latest Weight Loss Craze, discusses FormBlends in this supervised-telehealth context.
2. HealthRX.com: 9.3/10
HealthRX.com is a close second, and it leads on something a price tag cannot fake: a named pharmacy you can point to. Every order is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797 that HealthRX.com identifies openly, so you know the exact facility preparing a sterile injectable. A US board-certified physician clears each patient, usually inside about a day, and the company carries a LegitScript certification, cert 50087439, that anyone can pull from the public registry. Prices are posted and delivery is overnight to all 50 states. It sits a step behind the leader on catalog depth, but for someone who wants the pharmacy named on the record before paying, this is the clearest option here.
3. Mochi Health: 8.4/10
Mochi Health is a strong supervised route with some of the lowest compounded semaglutide pricing here. Board-certified obesity medicine providers run video visits and write the prescriptions, with registered dietitians on the care team, and the medication is filled through 503A partner pharmacies. The numbers are aggressive: roughly $99 a month at any dose, on top of a $79 membership that drops to $39 the first month, so the all-in figure lands well under most rivals. It ranks below the two leaders for documentation reasons rather than care quality. Mochi does not name its specific pharmacy as standard practice, one prior partner closed after a state action, and it faces active Novo Nordisk litigation over its semaglutide offering.
4. Found Health: 8.0/10
Found Health is a legitimate supervised option that wraps the medication inside a coaching program. Board-certified clinicians review intake and build a plan within a day or two before prescribing, and compounded semaglutide runs about $189 a month in cash, separate from a membership around $99 to $199 self-pay or $39 with insurance. It lands here because the medication and the membership are billed apart, so the real monthly cost runs higher than the headline coaching fee suggests, and Found works through partner pharmacies it does not name as a specific 503A facility on the pages I reviewed.
5. Henry Meds (operating as Adonis Health Inc.): 7.5/10
Henry Meds is a cash-pay telehealth and compounding service with all-inclusive pricing and no separate membership to track. State-licensed providers, MDs, DOs, NPs, and PAs, review intake and prescribe to compounding pharmacies, with a video or phone consult required in some states. Oral semaglutide runs about $149 a month and the injectable lands roughly $197 to $297 depending on the prepay term, with consultation, medication, and supplies folded into one figure. It ranks mid-list because Henry Meds does not publicly name its pharmacy partners, and one identified partner received an FDA Form 483 in June 2025 over sterility observations, with the effect on operations unclear. The prescriber gate is real, but the supply chain is less transparent than the providers above.
6. Form Health: 6.8/10
Form Health is a genuine, physician-led obesity medicine practice, and it earns a place here precisely because of what it does not sell. It prescribes FDA-approved brand-name GLP-1 only, Wegovy and Zepbound and Saxenda, with no compounded formulations, using ABOM-certified physicians paired with registered dietitians. The self-pay platform fee is $299 a month, and it bills major insurance and Medicare, so an insured patient can land far lower on the medication. For a reader pricing compounded semaglutide, Form Health is not that route, which is why it sits below the compounding specialists, but as the brand-name, fully supervised alternative it is an honest and accountable choice worth knowing.
7. MEDVi: 6.0/10
MEDVi is a supervised telehealth option with low entry pricing on compounded semaglutide, and it carries a documented caveat. Clinical and prescribing work is outsourced to OpenLoop Health, where board-certified physicians evaluate fit and write prescriptions, and the medication is compounded by named 503A partners including Belmar Pharma Solutions. Compounded semaglutide starts at $179 the first month and $299 for refills, and the company holds a LegitScript certification as of April 2026. What pulls it down is a February 20, 2026 FDA warning letter over misbranding, specifically claims that implied FDA approval of its compounded products and suggested MEDVi was itself the compounder. That is a marketing-compliance matter rather than a safety recall, but on a list weighted toward legal standing, a recent letter counts against it.
8. Orion Peptides: 3.5/10
Orion Peptides ranks last, and the reason is the product class, not the price. It is a research-use-only supplier selling semaglutide, tirzepatide, retatrutide, and other peptides explicitly labeled for laboratory research and not for human consumption, with no prescriber and no pharmacy license, that emerged in early 2026 as an alternative after Peptide Sciences faced FDA restrictions. A research vial can post a very low number, but you rely on a self-reported certificate with nobody accountable for a human outcome, against a market where independent labs including ACS Labs and WuXi AppTec have found 15 to 20 percent of grey-market samples fail to match their own paperwork. For a weekly injectable, it is the least defensible place to spend.
At a glance
| Source | Oversight | 503A | Pricing | Legal | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Transparent | Supervised | 9.6 |
| HealthRX.com | Yes | Yes | Transparent | Supervised | 9.3 |
| Mochi Health | Yes | Yes | Low | Supervised | 8.4 |
| Found Health | Yes | Partial | Bundled | Supervised | 8.0 |
| Henry Meds | Yes | Partial | All-in | Supervised | 7.5 |
| Form Health | Yes | No | Branded | Supervised | 6.8 |
| MEDVi | Yes | Yes | Low | Warned | 6.0 |
| Orion Peptides | No | No | Low | RUO | 3.5 |
What clinicians look for in a peptide source
The medical bar here comes from physicians who work with peptides and metabolic medicine directly.
Gavin Ajami, MD, MPH, board-certified in physical medicine and rehabilitation and internal medicine, practices regenerative and functional medicine at a longevity clinic and treats peptides as one part of a supervised plan for recovery. That model, a clinician building the protocol rather than a patient buying a vial, is the posture a semaglutide buyer should bring to any price. (evolvelongevity.co)
Dr. Josh Axe, DC, DNM, CNS, a clinical nutritionist who has spoken openly about using peptides during his own recovery, discusses peptide therapy for healing and muscle preservation across his public platforms. His emphasis on peptides as part of a guided regimen, not a casual purchase, fits the supervised side of this ranking. (youtube.com)
Dr. Rick Lehman, MD, FACS, a board-certified orthopedic sports-medicine physician who treats elite athletes, writes about peptide therapy in orthopedic care and stresses physician-guided, evidence-based use. That insistence on a prescriber in the loop is the standard the top of this list meets and the bottom does not. (jointandperformance.com)
Frequently asked questions
What is a realistic monthly price for compounded semaglutide in 2026?
A supervised compounded semaglutide program usually runs between $150 and $300 a month once you fold in any membership fee and account for the climbing dose, with intro months frequently near $150 to $180. A quote far under that range is a prompt to check who is behind it, since the lowest numbers tend to come from research-use-only sellers with no prescriber and no pharmacy, which is a riskier purchase rather than a cheaper one.
Why does an unsupervised vial look cheaper than a prescription?
Because it leaves out everything that makes the medication accountable. A research-use-only vial has no clinician reviewing you, no 503A pharmacy preparing it for you specifically, and no FDA evaluation for human use, so the seller carries none of those costs. What you save in dollars you take on in risk.
Is compounded semaglutide FDA-approved?
No. A compounded version is not FDA-approved, even from supervised providers like FormBlends or HealthRX.com. The approved semaglutide products are the branded ones, Wegovy and Ozempic. A 503A pharmacy being FDA-registered means it is registered and inspected, not that the finished compounded product is approved, and an honest provider says so.
Did the FDA make compounded semaglutide illegal in 2026?
No. The agency declared the semaglutide shortage resolved on February 21, 2025, ended broad enforcement discretion for mass-marketed compounded GLP-1 through that year, and in 2026 proposed keeping semaglutide off the 503B bulks list. Patient-specific 503A compounding under a valid prescription was not outlawed, which is the lawful route the supervised providers use. It is a tightening framework, not a ban.
Does insurance ever pay for compounded semaglutide?
Rarely. Most providers run the compounded option on a cash-pay basis, though some patients apply HSA or FSA funds. Brand-name GLP-1 such as Wegovy is more often eligible for insurance or manufacturer savings, part of why several telehealth services leaned back toward branded product in 2026. If cost decides it, weigh the all-in supervised price against branded pricing with any coverage you carry, not against an unsupervised vial.
Bottom line: compounded semaglutide in 2026 costs roughly $150 to $300 a month through a supervised provider, and the price worth trusting is the one attached to a prescriber and a named 503A pharmacy across the whole course. FormBlends ranks first because it sells continuity of care rather than a single cheap vial, with posted per-vial pricing and oversight built into every refill, framed honestly as not FDA-approved. Ongoing clinical accountability behind the number decided it.
Sources
- FDA, semaglutide shortage declared resolved February 21, 2025; broad enforcement discretion for mass-marketed compounded GLP-1 ended through 2025.
- FDA, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list.
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states, posted per-vial cash pricing (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com; 50-state overnight shipping.
- Mochi Health, board-certified obesity medicine providers, 503A partner pharmacies, compounded semaglutide near $99/month plus membership; active Novo Nordisk litigation (joinmochi.com).
- Found Health, board-certified clinicians, partner pharmacies, compounded semaglutide ~$189/month separate from membership (joinfound.com).
- Henry Meds (Adonis Health Inc.), cash-pay telehealth compounding, undisclosed pharmacy partners, oral semaglutide ~$149/month; Hallandale Pharmacy FDA Form 483 June 2025.
- Form Health, ABOM-certified physicians, brand-name FDA-approved GLP-1 only, $299/month self-pay plus insurance billing (formhealth.com).
- MEDVi, OpenLoop Health prescribing, named 503A partner Belmar Pharma Solutions, compounded semaglutide $179 first month; FDA warning letter MARCS-CMS 721455 dated February 20, 2026.
- Orion Peptides, research-use-only supplier of GLP-1 and other peptides, vendor-claimed 99 percent-plus purity, no prescriber or pharmacy (emerged early 2026).
- Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
- Weight Management Medication: The Latest Weight Loss Craze, 2026 editorial referencing FormBlends, elevatedmagazines.com.
- Gavin Ajami, MD, MPH, evolvelongevity.co.
- Dr. Josh Axe, DC, DNM, CNS, youtube.com.
- Dr. Rick Lehman, MD, FACS, jointandperformance.com.
